Page last updated: 2024-09-03

imatinib mesylate and Thymoma

imatinib mesylate has been researched along with Thymoma in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (42.86)	29.6817
2010's	4 (57.14)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Giaccone, G; Hogendoorn, PC; Rajan, A; Ruijter, R; Smit, E; van Groeningen, C	1
Hamada, S; Hirota, S; Masago, K; Mio, T; Mishima, M	1
Buti, S; Donini, M; Garagnani, L; Passalacqua, R; Rossi, G; Schirosi, L; Sergio, P	1
Buti, S; Buttitta, F; Calabrese, F; Cavazza, A; Di Chiara, F; Felicioni, L; Garagnani, L; Marchetti, A; Mengoli, MC; Migaldi, M; Nannini, N; Nicoli, D; Rea, F; Rossi, G; Sartori, G; Schirosi, L; Valli, R	1
Buti, S; Donini, M; Passalacqua, R; Rossi, G; Rossi, V; Sergio, P	1
Brink, I; Dirnhofer, S; Hartmann, M; Jakob, A; Marx, A; Mikesch, K; Ströbel, P	1
Belhorn, T; Blatt, J; Fordham, LA; McDonald, M; McLean, T; Smith, SV; Woods, C	1

Trials

1 trial(s) available for imatinib mesylate and Thymoma

Article	Year
Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease Progression; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Survival Rate; Thymoma; Thymus Neoplasms; Treatment Outcome	2009

Article

Year

Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:10

Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease Progression; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Survival Rate; Thymoma; Thymus Neoplasms; Treatment Outcome

2009

Other Studies

6 other study(ies) available for imatinib mesylate and Thymoma

Article	Year
Good clinical response to imatinib mesylate in atypical thymic carcinoid With KIT overexpression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jan-01, Volume: 29, Issue:1 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Thymoma; Thymus Neoplasms	2011
Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Nov-20, Volume: 29, Issue:33 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Thymoma; Thymus Neoplasms	2011
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Benzenesulfonates; Carcinoid Tumor; Carcinoma, Squamous Cell; CD5 Antigens; DNA Mutational Analysis; Enzyme Activation; Female; Genetic Association Studies; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation, Missense; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thymoma; Thymus Neoplasms; Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins	2012
When a thymic carcinoma "becomes" a GIST. Lung cancer (Amsterdam, Netherlands), 2013, Volume: 80, Issue:1 Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Thymoma; Thymus Neoplasms; Treatment Failure; Treatment Outcome	2013
Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. The New England journal of medicine, 2004, Jun-17, Volume: 350, Issue:25 Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Fatal Outcome; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Sequence Analysis, DNA; Sequence Deletion; Thymoma; Thymus Neoplasms	2004
Thymic carcinoma in a child with HIV infection. Pediatric blood & cancer, 2007, Volume: 49, Issue:7 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Disease Progression; Follow-Up Studies; HIV Infections; Humans; Imatinib Mesylate; Liver Neoplasms; Lung Neoplasms; Male; Mediastinal Cyst; Piperazines; Pyrimidines; Remission Induction; Thymoma; Thymus Neoplasms; Tomography, X-Ray Computed; Treatment Outcome	2007